Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NanoSight to Supply Instrumentation for Wellcome Trust Technology Development Grant

Published: Friday, May 22, 2009
Last Updated: Friday, May 22, 2009
Bookmark and Share
NanoSight’s methodologies aimed at measuring cellular nanoparticles in plasma and urine as biomarkers of a broad range of human disease conditions.

NanoSight announces its involvement in the research and development of a new generation of novel instrumentation and methodologies aimed at measuring cellular nanoparticles in plasma and urine as biomarkers of a broad range of human disease conditions.

The research will be led by a world-class team from the University of Oxford which has recently been awarded a Wellcome Trust Technology Development Grant to work on the detection and characterization of nanoparticles in the early detection of human disease.

The team, which is led by Professor Ian Sargent at the Women's Centre of the John Radcliffe Hospital and is part of the Oxford Biomedical Research Centre, includes Professor Chris Redman (Obstetrics and Gynaecology), Dr Paul Harrison (Haemophilia and Thrombosis Centre), Professor Adrian Harris (Cancer Research UK) and Professor Peter Dobson (Begbroke Science Park). Other collaborators include Dr Leanne Hodson and Dr Frederick Karpe of the Oxford Centre for Diabetes, Endocrinology and Metabolism.

This exciting project involves the detection in the bloodstream of tiny fragments of cells, microparticles (100nm -1µm) and exosomes (30nm - 100nm), which are important for how cells communicate with each other. The numbers of these particles have been found to be significantly raised in the blood of patients with a number of diseases including heart disease, diabetes, pre-eclampsia, clotting problems and cancer, raising the possibility that measuring these particles in blood could be used to predict those at risk. However, their detection and size distribution measurement pose considerable challenges.

Alerted to NanoSight’s capabilities by Professor Dobson who recognized the fit between Professor Sargent’s needs and the NanoSight technology of which he was an early adopter, the Oxford group discussed their requirements with NanoSight’s scientists and, following very promising initial results, successfully applied for and were awarded £322,000 of Wellcome Trust funding in support of this important 3 year project.

Based on their innovative technology and capabilities, a novel fluorescence variant of NanoSight’s existing instrumentation will be developed by NanoSight in collaboration with the Oxford scientists to enable these micro- and nanoparticles to be detected and characterized in plasma and urine samples for the first time. By breaking through the limitations of existing fluorescence microparticle technology (such a flow cytometry) NanoSight hope to help open up a new class of diagnostic biomarkers in the fight against some of the most common and important diseases to afflict humans.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Studying behaviour of Exosomes and Microvesicles using Nanoparticle Tracking Analysis
Dr Gregory Gores of the Mayo Clinic in Rochester, Minnesota is using NTA to study extracellular vesicles.
Tuesday, November 19, 2013
NanoSight Acquired by Malvern Instruments
The acquisition of NanoSight by Malvern Instruments was completed on Friday 27 September.
Monday, September 30, 2013
NanoSight Wins a 2013 Queen's Award for Enterprise – Innovation
Award follows on from their 2012 Queen's Award for Enterprise for International Trade.
Monday, April 22, 2013
Nanoparticle Tracking Analysis Technology Facilitates Cancer Metastasis Research
NanoSight reports on the breakthrough cancer metastasis research of Dr. Hector Peinado Selgas and Dr. David Lyden's research team from Weill Cornell Medical College.
Tuesday, November 13, 2012
Conference Highlights Biomarker Detection Role for NanoSight
Oxford researchers presented new data applying NTA to size and count both cellular microvesicles and exosomes at a low concentration.
Saturday, October 09, 2010
The Forschungszentrum Dresden-Rossendorf Chooses NanoSight to Characterize Magnetic Nanoparticles
NanoSight’s LM-20 nanoparticle characterization system to study magnetic nanoparticles for applications in cancer therapy.
Wednesday, August 18, 2010
NanoSight Holds First European Users Meeting on Nanoparticle Characterization in Langen, Germany
Meeting provided an excellent opportunity to present new data using nanoparticle tracking analysis, NTA.
Thursday, July 15, 2010
NanoSight holds first European users meeting on nanoparticle characterization in Langen, Germany
NanoSight, world-leading manufacturers of unique nanoparticle characterization technology, together with distributor partners Schaefer Technologie, have recently held a meeting of users of their successful range of nanoparticle tracking analysis instruments in Langen, Germany.
Tuesday, July 13, 2010
University of Leicester Uses NanoSight to Characterize Marine Viruses and Bacteriophages
Microbiologists use NanoSight system to study cyanobacteria and their viruses which involves the accurate enumeration of viral particles.
Wednesday, June 09, 2010
Leiden University uses NanoSight Characterization System to Aid their Drug Delivery Research Programs
NanoSight helps the research group to focus on vaccine delivery and on protein formulation and characterization with respect to immunogenicity.
Wednesday, February 24, 2010
Strathclyde’s Nanometrology Centre Selects NanoSight to Develop New Biosensors
University of Strathclyde has selected an LM-10 characterization system to aid in their research and development of new biosensors.
Wednesday, November 11, 2009
NanoSight Nanoparticle Detection Technique Contributes to Virus Production to Counter MRSA
Researchers at the University of Strathclyde use virus particle detection and counting using Nanoparticle Tracking Analysis to combat MRSA.
Tuesday, December 09, 2008
NanoSight Receives £925,000 in Funding Round to Expand their Nanoparticle Characterization Business
The new round of financing which will enable the company to expand the business with the development of new products and sales channels in the US market.
Thursday, November 06, 2008
Nanosight Angel Investor Round
The angel investor round increases its shareholder base and complements previous investments by Venture Capital companies.
Monday, September 10, 2007
NanoSight Raises £250k in Second Tranche of Fundraising
The investment supports Company’s current sales drive and develops capabilities in nanoparticle analysis.
Wednesday, September 27, 2006
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!